Alligator Bioscience AB publishes prospectus for Initial Public Offering on Nasdaq Stockholm
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER ...
Nomination committee appointed in respect of AGM 2017 in Alligator Bioscience AB (Publ)
According to the instruction for Nomination Committee in Alligator Bioscience AB (publ) adopted at the annual general meeting held on 20 Apr ...
Alligator Bioscience AB intends to list its shares on Nasdaq Stockholm
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER ...
Alligator Bioscience informs that dosing has started in a second clinical phase I study with the CD40 Agonistic Immuno-Oncology Antibody ADC-1013
– Janssen assumes responsibility for all future clinical studies Alligator started dosing in the first clinical phase I dose escalatio ...
Alligator contracts BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015
Alligator Bioscience AB is a privately held Swedish biotech company developing immuno-oncology antibodies for tumor-directed immunotherapy. ...
Alligator receives the SwedenBIO Award!
Alligator Bioscience has received the SwedenBIO Award for ”exceptional achievements within the life-science industry”. This is yet another c ...
First milestone payment for ADC-1013
Alligator Bioscience AB is a privately held Swedish biotech company developing immuno-oncology antibodies for directed immunotherapy of canc ...
Documentation of proposals for the annual shareholder’s meeting
After proofreading minor corrections has been made. Comprehensive income and Financial position are however intact. Complete proposal, item ...
Communication of proposals for the extraordinary shareholder’s meeting on 14 March, 2016
Major shareholders have now submitted their proposals regarding items 8 and 9 in the published notice. Proposal item 8: The number of board ...